Home Newsfeeds Bellerophon Therapeutics Q2 EPS $(0.43) Down From $(0.36) YoY

Bellerophon Therapeutics Q2 EPS $(0.43) Down From $(0.36) YoY

Bellerophon Therapeutics (NASDAQ:BLPH) reported quarterly losses of $(0.43) per share. This is a 19.44 percent decrease over losses of $(0.36) per share from the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Bellerophon Therapeutics (NASDAQ:BLPH) reported quarterly losses of $(0.43) per share. This is a 19.44 percent decrease over losses of $(0.36) per share from the same period last year.

SpaceX Rival Backed By Boeing And Lockheed Martin Reportedly Up For Sale

By Anan Ashraf

March 3, 8:31 AM

Elon Musk-owned SpaceX competitor United Launch Alliance, or ULA, is reportedly up for sale.

AMZN

Alaunos Therapeutics Highlights Data From TCR-T Library Phase 1/2 Trial At The CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference; Data To Be Presented On Friday, September 30

By Benzinga Newsdesk

September 21, 8:33 AM

First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion Sleeping Beauty TCR-T cell therapy had a manageable safety

TCRT

Western Digital Likely To Report Q1 Loss; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

October 30, 2:54 AM

Western Digital Corporation (NASDAQ: WDC) is expected to release financial results for its first quarter fiscal year 2024, before the opening bell on Oct. 30, 2023.

WDC

International Game Technology, PFSweb And Other Big Stocks Moving Higher On Thursday

By Lisa Levin

September 14, 10:25 AM

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session. PFSweb, Inc. (NASDAQ: PFSW) jumped 48.3% to $7.43 after GXO Logistics announced it will acquire the company.

ACB

Bellerophon Therapeutics Q2 EPS $(0.43) Down From $(0.36) YoY

Related Posts

SpaceX Rival Backed By Boeing And Lockheed Martin Reportedly Up For Sale

Alaunos Therapeutics Highlights Data From TCR-T Library Phase 1/2 Trial At The CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference; Data To Be Presented On Friday, September 30

Western Digital Likely To Report Q1 Loss; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

International Game Technology, PFSweb And Other Big Stocks Moving Higher On Thursday